World news: PKvitality Kwatch CGM - no pain

lut23

World news: PKvitality Kwatch CGM - no pain

New vision of CGM

The PKvitality team wants to hit the CGM market. Instead of making gradual improvements, they introduce a new idea of CGM. Their goal is to improve the availability of CGM for people with type 1 and type 2 diabetes.

The offer can be issued immediately. For a radical reduction of costs. There are no devices associated with data transfer, e.g. a transmitter, as is the case when running CGM.

 

Compare to traditional CGM

CGM systems have evolved over the last decade. Today, they use mobile applications to improve access to their data and deliver notifications. CGM sensors and receivers are also smaller. The user experience of installing and carrying the sensor requires caution, rotation of the site and management of skin irritations caused by adhesives. However, disposable sensors are quite expensive and should be replaced every 7-14 days.

For many people, the problem is also arousing general interest by the environment. Many people ask what a sensor installed on the skin is and what it is needed for. It does not quite suit many users.

PKvitality strives to improve the overall user experience and reduce user costs. For this purpose, a new sensor has been developed, mounted under the watch, which has a lot of micropoints in contact with the surface of the skin. Putting on a watch with a sensor is painless, and the contact points of the sensor "penetrate" into the microscopic surface of the skin without pain, without creating scars or bleeding. The sensor is placed gently on the skin via the watch strap. The rotation of the watch is not necessary and only one place can be used.

 

Sensors live time

The sensor works for 7 days and the potam should be replaced with a new one, without changing the place. The watch has a fast microprocessor, a capacious battery and typical applications for "smartwatch". This design reduces the components of the sensor only to the micropoints and their electrical connection to the watch, which greatly simplifies production costs. This is a combination of a very user-friendly CGM watch and very cheap sensors that will eventually benefit from using CGM for most people with CT1 and CT2.

Compared with the traditional CGM system, there is no needle, no electrode, no procedure for "injecting" the sensor.

 

SKinTaste® technology

The company first developed the patented SKinTaste® technology, which is a matrix of biosensors, using micropores of length <1 mm to collect and analyze the chemical composition of interstitial fluid located just below the surface of the skin.

This breakthrough technology has the ability to analyze key physiological indicators of the skin without the need for a blood sample analysis.

Clinical device tests will start in Europe next year, if they fall out correctly, the device will go to retail.

We keep our fingers crossed!

 

source: www.insulinnation.com


     

lut  23